Investigators found that patients with mucous membrane pemphigoid, especially those with severe disease, face increased risks of squamous and basal cell carcinomas.
A longitudinal study across two major U.S. health databases found nucleoside reverse transcriptase inhibitors to be associated with reduced Alzheimer's disease incidence.
A hospital-derived strain of Pseudomonas aeruginosa was found to degrade medical plastic, use it as food, and form stronger biofilms, revealing new risks for device-related infections.
The FDA has cleared the first blood-based test to aid in diagnosing Alzheimer’s disease, offering a less invasive alternative to positron emission tomography scans and cerebrospinal fluid testing for cognitively impaired patients.
The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.